STOCK TITAN

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Monopar Therapeutics (Nasdaq: MNPR) has announced the pricing of a public offering of common stock at $16.25 per share, aiming to raise approximately $19.2 million in gross proceeds. The offering, expected to close on October 30, 2024, features participation from notable investors including Janus Henderson Investors and RA Capital Management. Rodman & Renshaw serves as the exclusive placement agent. The company plans to use the proceeds for general corporate purposes, including research and development, clinical trials, product manufacturing, and working capital.

Monopar Therapeutics (Nasdaq: MNPR) ha annunciato il prezzo di un offerta pubblica di azioni ordinarie a $16.25 per azione, con l'obiettivo di raccogliere circa $19.2 milioni in proventi lordi. L'offerta, prevista per chiudere il 30 ottobre 2024, vede la partecipazione di investitori di rilievo tra cui Janus Henderson Investors e RA Capital Management. Rodman & Renshaw funge da agente di collocamento esclusivo. L'azienda prevede di utilizzare i proventi per scopi aziendali generali, compresi ricerca e sviluppo, prove cliniche, produzione di prodotti e capitale circolante.

Monopar Therapeutics (Nasdaq: MNPR) ha anunciado el precio de una oferta pública de acciones ordinarias a $16.25 por acción, con el objetivo de recaudar aproximadamente $19.2 millones en ingresos brutos. Se espera que la oferta cierre el 30 de octubre de 2024 y cuenta con la participación de inversores notables, incluyendo a Janus Henderson Investors y RA Capital Management. Rodman & Renshaw actúa como agente de colocación exclusivo. La empresa planea usar los ingresos para fines corporativos generales, incluidos investigación y desarrollo, ensayos clínicos, fabricación de productos y capital de trabajo.

모노파 테라퓨틱스 (Nasdaq: MNPR)는 공모의 가격을 주당 $16.25로 발표하며 약 $19.2 백만의 총 수익을 목표로 하고 있습니다. 이 공모는 2024년 10월 30일에 마감될 예정이며, Janus Henderson Investors와 RA Capital Management 등 저명한 투자자들이 참여하고 있습니다. Rodman & Renshaw는 독점 매placement 에이전트로 활동합니다. 회사는 이 수익금을 연구 개발, 임상 시험, 제품 제조 및 운영 자본을 포함한 일반 기업 목적에 사용할 계획입니다.

Monopar Therapeutics (Nasdaq: MNPR) a annoncé le prix d'une offre publique d'actions ordinaires fixé à 16,25 $ par action, visant à lever environ 19,2 millions $ en produits bruts. L'offre, qui devrait se clôturer le 30 octobre 2024, bénéficie de la participation d'investisseurs notables, y compris Janus Henderson Investors et RA Capital Management. Rodman & Renshaw agit en tant qu'agent de placement exclusif. L'entreprise prévoit d'utiliser les produits pour des fins d'entreprise générales, y compris la recherche et le développement, les essais cliniques, la fabrication de produits et le fonds de roulement.

Monopar Therapeutics (Nasdaq: MNPR) hat die Preisgestaltung eines öffentlichen Angebots von Stammaktien zu einem Preis von 16,25 $ pro Aktie bekannt gegeben, mit dem Ziel, etwa 19,2 Millionen $ brutto zu erzielen. Es wird erwartet, dass das Angebot am 30. Oktober 2024 abgeschlossen wird und namhafte Investoren wie Janus Henderson Investors und RA Capital Management teilnehmen. Rodman & Renshaw fungiert als exklusive Platzierungsagentur. Das Unternehmen plant, die Erlöse für allgemeine Unternehmenszwecke zu verwenden, einschließlich Forschung und Entwicklung, klinischen Studien, Produktfertigung und Betriebskapital.

Positive
  • Secured $19.2 million in gross proceeds through public offering
  • Attracted notable institutional investors including Janus Henderson and RA Capital Management
  • Funds will support R&D, clinical trials, and manufacturing operations
Negative
  • Potential dilution of existing shareholders' equity
  • Additional offering expenses will reduce net proceeds
  • Share price dilution at $16.25 per share

Insights

This $19.2 million public offering at $16.25 per share represents a significant capital raise for Monopar Therapeutics, attracting notable investors including Janus Henderson and RA Capital Management. The participation of these well-known institutional investors adds credibility to the offering and suggests confidence in the company's pipeline.

The funding strengthens Monopar's balance sheet and provides runway for advancing their clinical programs. However, investors should note this offering will result in dilution for existing shareholders. The use of proceeds for R&D, clinical trials and manufacturing indicates the company is prioritizing pipeline development over immediate profitability, which is typical for clinical-stage biotechs.

The pricing and successful placement with quality institutional investors despite challenging market conditions for biotech companies is a positive signal. The shelf registration and best efforts structure suggests careful consideration of market dynamics to optimize the capital raise.

WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of its best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The offering is expected to close on October 30, 2024, subject to satisfaction of customary closing conditions.

Janus Henderson Investors, RA Capital Management, L.P. and other notable growth and life science investors participated in the offering.

Rodman & Renshaw LLC is acting as the exclusive placement agent for the offering.

Monopar Therapeutics intends to use the net proceeds from the offering for general corporate purposes, which may include research and development expenditures, clinical trial expenditures, manufacture and supply of product and working capital.

The securities are being offered and sold pursuant to a "shelf" registration statement on Form S-3 (File No. 333-268935), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 21, 2022, and declared effective on January 4, 2023. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC and is available on its website at www.sec.gov.  Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting Rodman & Renshaw LLC at 600 Lexington Avenue, 32nd Floor, New York, NY 10022, by email at info@rodm.com, or by telephone at (212) 540-4414. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.

About Monopar Therapeutics

Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN-1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering and the anticipated use of proceeds therefrom. The forward-looking statements involve risks and uncertainties including, but not limited to: our near term ability to raise sufficient funds in order for us to support continued clinical, regulatory and commercial development of our programs and to make contractual upfront and future milestone payments, as well as our ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; uncertainties related to the regulatory discussions we intend to initiate related to ALXN-1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety, of any products for which we receive marketing approval, and our ability to competitively market any such products as compared to larger pharmaceutical firms; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

CONTACT: 
Monopar Therapeutics Inc.
Investor Relations

Karthik Radhakrishnan 
Chief Financial Officer
karthik@monopartx.com


FAQ

What is the price per share for Monopar Therapeutics (MNPR) October 2024 public offering?

Monopar Therapeutics priced its public offering at $16.25 per share.

How much money is Monopar Therapeutics (MNPR) raising in its October 2024 offering?

Monopar Therapeutics is raising approximately $19.2 million in gross proceeds before deducting placement agent fees and other offering expenses.

When will Monopar Therapeutics (MNPR) October 2024 public offering close?

The offering is expected to close on October 30, 2024, subject to customary closing conditions.

Who are the major investors in Monopar Therapeutics (MNPR) October 2024 public offering?

Janus Henderson Investors and RA Capital Management, L.P. are among the notable growth and life science investors participating in the offering.

Monopar Therapeutics Inc.

NASDAQ:MNPR

MNPR Rankings

MNPR Latest News

MNPR Stock Data

49.39M
5.14M
53.33%
7.84%
1.42%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WILMETTE